This is a promising signal, not proof
Phase 3 data on retatrutide (triple GLP-1/GIP/glucagon agonist) showing nearly 29% weight loss, the pending approval of CagriSema (GLP-1/amylin combination), and the arrival of oral non-peptide GLP-1 agonists like orforglipron all suggest we are at the start of a metabolic therapeutics renaissance
While their clinical standards are high, they have faced criticism on Trustpilot (3.4 rating) regarding billing and scheduling hiccups
GH also boosts IGF-1 production, which supports thermogenesis and can increase daily calorie burn meaningfully over time
Without drug shortage exemption protection, prescribing compounded GLP-1s now poses serious legal risks for medical providers
Thankfully, Felix makes requesting online semaglutide prescriptions a seamless process